Our January 2024 Month in Review spotlights the FDA approval of a new indication of dupilumab (Dupixent) for pediatric eosinophilic esophagitis, new clinical trial data, and research about the prevention and management of IBD.
We sat down with Julie Khlevner, MD, to discuss new efficacy endpoint data from the phase 3 study used to support the FDA approval of linaclotide for pediatric functional constipation.